Global biopharmaceutical company MSD GCC has won the prestigious ’Medical Education Partner of the Year’ Award from the Emirates Oncology Society (EOS). This accolade is a testament to MSD’s commitment to advancing healthcare by developing innovative multidisciplinary educational programmes.
Commenting on the achievement, Professor Humaid Al Shamsi, President of the Emirates Oncology Society, said: “We are pleased to honour MSD, acknowledging their steadfast dedication to advancing healthcare through the development of innovative educational and multidisciplinary programmes. This recognition underscores MSD’s dedication to improving healthcare standards and outcomes, ultimately benefiting patients and the medical community. We look forward to continuing our collaborative efforts to further advance various aspects of the healthcare industry”.
The award recognizes MSD’s commitment to advancing the healthcare industry and improving patient care through the development of unique and innovative programmes such as ‘Angels’, designed to equip nurses with the knowledge and skills needed to manage immune-related adverse events efficiently.
Other programmes include “Link MdT” which focuses on strengthening Multidisciplinary Team (MDT) practices by building connections between Lung cancer MDTs in the Gulf region and established lung cancer MDTs in other countries. Through this programme, MSD is facilitating collaborations and knowledge exchange, which contribute to enhancing the quality of patient care and expertise in lung cancer management.
MSD also developed the ‘Networks of Immuno-oncology’ programme that establishes connections and networks among oncologists and provides them with the latest updates related to cancer immuno- therapy. Through this program, oncologists can share their clinical experience and best practices in the field. With this, MSD aims to advance the effective application of immunotherapy in the treatment of cancer and improve patient outcomes.
